Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.

Mayer, Katharina; Bernlochner, Isabell; Braun, Siegmund; Schulz, Stefanie; Orban, Martin; Morath, Tanja; Cala, Lisena; Hoppmann, Petra; Schunkert, Heribert; Laugwitz, Karl-Ludwig; Kastrati, Adnan; Sibbing, Dirk

doi:10.1016/j.jacc.2014.05.049

journal article

Title:: Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.
Document type:: Journal Article; Article
Author(s):: Mayer, Katharina; Bernlochner, Isabell; Braun, Siegmund; Schulz, Stefanie; Orban, Martin; Morath, Tanja; Cala, Lisena; Hoppmann, Petra; Schunkert, Heribert; Laugwitz, Karl-Ludwig; Kastrati, Adnan; Sibbing, Dirk
Abstract:: Aspirin administration, as part of a dual antiplatelet treatment regimen, is essential for patients undergoing percutaneous coronary intervention (PCI). Although the correlation between high on-clopidogrel treatment platelet reactivity (HCPR) and clinical outcome is well established, data for high on-aspirin treatment platelet reactivity (HAPR) are conflicting.The aim of the ISAR-ASPI (Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition) registry was to assess the value of HAPR as a possible prognostic biomarker in PCI-treated patients with regard to clinical outcome.From February 2007 to May 2013, we identified 7,090 consecutive PCI-treated patients with measured on-aspirin treatment platelet aggregation values directly before PCI. Platelet function was assessed with a Multiplate analyzer. The primary endpoint was death or stent thrombosis (ST) at 1 year.The upper quintile of patients (n = 1,414), according to Multiplate measurements, was defined as the HAPR cohort. Compared with non-HAPR patients (n = 5,676), HAPR patients showed a significantly higher risk of death or ST at 1 year (6.2% vs. 3.7%, respectively; odds ratio [OR]: 1.78; 95% confidence interval [CI]: 1.39 to 2.27; p < 0.0001). HAPR was found to be an independent predictor of the primary outcome (adjusted hazard ratio [HRadj]: 1.46; 95% CI: 1.12 to 1.89; p = 0.005).HAPR, measured at the time point of the PCI, is associated with a higher risk for death or ST during the first year after PCI. Present data are in support of the addition of HAPR to a panel of prognostic biomarkers in PCI-treated patients.
Journal title abbreviation:: J Am Coll Cardiol
Year:: 2014
Journal volume:: 64
Journal issue:: 9
Pages contribution:: 863-71
Language:: eng
Fulltext / DOI:: doi:10.1016/j.jacc.2014.05.049
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/25169169
Print-ISSN:: 0735-1097
TUM Institution:: I. Medizinische Klinik und Poliklinik (Kardiologie); Institut für Laboratoriumsmedizin (keine SAP-Zuordnung!); Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (Prof. Schunkert)
BibTeX